NCT05065840
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
Active, Not Recruiting
NAAges 18–45InterventionalPreventionEmory UniversityInvestigator-initiated
~267 participants
Updated 2026-05-14 on ClinicalTrials.gov
What's tested:CDC 4 Pillars Program
At a glance
Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of patients initiating the HPV vaccine
Measured over 24 months post baseline
Conditions
Where it's being run
4 sites across 1 statesGeorgia4
Study leadership
- Jessica Wells, PhD, RN · PRINCIPAL_INVESTIGATOR · Emory University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
HIV positive
18-45 years of age
Can read and speak English
Capable of providing informed consent
Has not previously received three series HPV vaccine
No contraindications to receiving HPV vaccine (i.e. history of anaphylactic allergy to later, an immediate hypersensitivity to yeast, current moderate or severe acute illness, and/or are currently pregnant).
Exclusion
Has contraindications to receiving the HPV vaccine i.e., history of an anaphylactic allergy to latex, an immediate hypersensitivity to yeast, current moderate or severe acute illness, and/or are currently pregnant)
What this trial measures
- Number of patients initiating the HPV vaccine24 months post baseline
Initiation of the HPV vaccine is defined as receiving the first or second immunization from the series. This variable will be measured by electronic medical records and GRITS at 24 months post baseline.